5 Key Takeaways

• 1

  Tiespectus is a bispecific agent that inhibits VEGF and activates the Tie2 pathway for treating wet age-related macular degeneration.

• 2

  The phase 2 trial involved 20 treatment-naïve eyes with AMD, testing 7 mg and 10 mg doses of tiespectus.

• 3

  Results showed significant improvements in visual acuity, with an average gain of over 7 letters by week 12.

• 4

  Tiespectus treatment resulted in a reduction of retinal thickness by over 215 µm by week 12.

• 5

  No ocular adverse events related to tiespectus were reported in the trial, indicating a favorable safety profile.